Table 2.
Evaluation of immune cell subsets in colorectal cancer patients prior to and after 30 d of standard-of-care anticancer therapy.
| Baseline | Post 30 d | N | |
|---|---|---|---|
| Number of PBMCs (x103/µL) | 2.1 (1.9–2.6) | 2.1 (1.5–2.7) | 23 |
| CD4+ T cells (%) | 47 (31–53) | 47 (39–52) | 23 |
| Number of CD4+ T cells (x103/µL) | 0.9 (0.6–1.1) | 1.0 (0.7–1.3) | 23 |
| CD8+ T cells (%) | 24 (15–30) | 22 (19–26) | 23 |
| Number of CD8+ T cells (x103/µL) | 0.5 (0.4–0.8) | 0.5 (0.3–0.6) | 23 |
| Treg of CD4+ T cells (%) | 5.8 (4.7–8.0) | 5.7 (4.6–6.7) | 23 |
| Treg of PBMCs (%) | 2.6 (2.1–3.3) | 2.6 (1.5–3.2) | 23 |
| Number of Tregs (x103/µL) | 0.06 (0.04–0.07) | 0.06 (0.03–0.07) | 23 |
| CD4+ Teff:Treg Ratio | 17.0 (12.4–21.3) | 17.6 (14.9–21.7) | 23 |
| CD8+ Teff:Treg Ratio | 9.9 (6.1–15.0) | 8.7 (5.7–16.0) | 23 |
| CD4+:CD8+ Ratio | 1.9 (1.1–3.1) | 2.0 (1.4–3.2) | 23 |
| Treg suppression (%) | 44 (34.5–51) | 39 (28.0–58.0) | 13 |
Twenty-three first-line metastatic colorectal cancer patients were enrolled and treated with FOLFIRI therapy. PBMCs were collected at baseline and post 30 d of therapy, and subjected to flow cytometry analysis as described in Methods section. Values are the median (interquartile range). Wilcoxon test between baseline and post 30 d showed no statistical differences for any of the immune cell subsets studied, or for the Treg suppression assay.
PBMCs, peripheral blood mononuclear cells; Treg, regulatory T cells.